HC Wainwright gives Septerna a Buy rating and $26 price target citing multiple upcoming catalysts. Septerna trades below cash value despite a Novo Nordisk partnership and a promising drug pipeline.

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic diseases, as it pays $200 million for rights to preclinical-stage ...

Recently, Novo Nordisk signed a $2.2 billion deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, T2D and other cardiometabolic diseases.

Novo also recently partnered with another biotech start-up, Septerna, to develop small molecules for weight loss and metabolic disorders. That collaboration is worth up to $2.2 billion between up ...

This week, Novo signed a $812 million weight-loss drug license deal with U.S. biotech Deep Apple. In May, it announced a deal with San Francisco, Calif.-based Septerna to develop oral small ...

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...